Home › Companies › LRMR

Larimar Therapeutics, Inc.

LRMR Rare disease Lead: Phase 3 3 Biotech Distilled articles ↓

Neurology Protein

Most recent annual filing: 2026-03-15

Pipeline (1 active programs)

nomlabofusp

Protein Target: frataxin, FXN

Friedreich's Ataxia Phase 3 subcutaneous

Technology platforms

CPP

Cell penetrating peptide (CPP) technology platform enabling therapeutic molecules to cross cell membranes and reach intracellular targets, including mitochondria; focused on rare and orphan diseases characterized by deficiencies in or alterations of intracellular content or activity

Biotech Distilled coverage (3)

2026-03-21 UPDATE: Larimar (LRMR) - The $63 Million Tell 🔒 Paid
2026-02-28 UPDATE: Larimar (LRMR) - The FDA Blinks, Larimar Squeezes, and the Dilution Gap Closes 🔒 Paid
2026-01-11 Larimar Therapeutics (LRMR): Scientific Deep Dive for Nomlabofusp and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.